Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-2020 (COVI-AMG) in Mild COVID-19
NCT04734860Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of plutavimab in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Planned start Apr 2021; status: withdrawn.
02
Drugs
plutavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04734860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734860.